Ginkgo bioworks awarded $9.4 million in partnership with carnegie mellon university to develop implantable cell-based bioelectronic devices for disease treatment under arpa-h's react program

Ginkgo bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders boston , dec. 17, 2024 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with carnegie mellon university to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. this initiative is part of the advanced research projects agency for health's (arpa-h) resilient extended automatic cell therapies (react) program.
DNA Ratings Summary
DNA Quant Ranking